Skip to content

Effects of Intranasal Dexmedetomidine Combined with Epidural Analgesia of Nalbuphine, Sufentanil and Ropivacaine on Labor Analgesia Efficacy and Postpartum Depression: A Randomized, Double-Blind, Controlled Clinical Study

Effects of Intranasal Dexmedetomidine Combined with Epidural Analgesia of Nalbuphine, Sufentanil and Ropivacaine on Labor Analgesia Efficacy and Postpartum Depression: A Randomized, Double-Blind, Controlled Clinical Study

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2600123653
Enrollment
Unknown
Registered
2026-04-28
Start date
2026-04-30
Completion date
Unknown
Last updated
2026-05-04

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Postpartum Depression

Interventions

Normal Saline Group 2(C2):An equal volume of normal saline was sprayed into each bilateral nostril 15 minutes prior to puncture.
Normal Saline Group 1(C1):An equal volume of normal saline was sprayed into the unilateral nostril 15 minutes prior to puncture.
Experimental Group 2(S2):A dose of 25 µg dexmedetomidine was administered to each of the bilateral nostrils 15 minutes prior to puncture.
Experimental Group 1(S1):A dose of 25 µg dexmedetomidine was administered via nasal spray into the unilateral nostril 15 minutes prior to the performance of puncture.

Sponsors

Hefei First People's Hospital
Lead Sponsor

Eligibility

Sex/Gender
Female
Age
21 Years to 39 Years

Inclusion criteria

Inclusion criteria: 1. Both primiparas and multiparas are eligible. 2. Age 21–39 years, 26 <= BMI <= 33 kg/m^2. 3. ASA I or Level I, full-term, cephalic presentation, single fetus. 4. Complete relevant prenatal examinations before labor analgesia; cervical dilation 2–3 cm, meeting criteria for normal delivery. 5. Able to cooperate with procedures: conscious and able to change positions as required. 6. Fully informed about the clinical trial, voluntarily agrees to participate, and signs informed consent. 7. All parturients have no contraindications to anesthesia prior to the procedure, no history of opioid allergy, no pregnancy-related diseases, and no mental disorders.

Exclusion criteria

Exclusion criteria: 1. Infection at the puncture site; 2. Presence of blood disorders; 3. History of allergy to the investigational drug; 4. Presence of neurological disorders; 5. Unable to communicate normally with the investigator; 6. Individuals with psychological or psychiatric disorders; 7. History of long-term opioid use; 8. Patients judged to lack consent capacity; 9. Participation in other clinical trials recently; 10. Known allergy to a2 receptor agonists;

Design outcomes

Primary

MeasureTime frame
maternal cooperation;Postpartum Depression;

Secondary

MeasureTime frame
PCEA demand presses and total analgesic consumption;Pain intensity and sedation level;Labor progress of parturients;Degree of neonatal asphyxia and resuscitation requirements;Intraoperative and postoperative adverse events;

Countries

China

Contacts

Public ContactYang Heng

Hefei First People's Hospital

yangh999@yeah.net+86 551 8213 9210

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: May 7, 2026